← SynDRA
ZANUBRUTINIB
SynDRA canonical compound SYN0038652 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor |
|---|
All known targets
- BTK
- BLK
- BMX
- EGFR
- ERBB2
- ERBB4
- FGR
- FRK
- GP6
- ITK
- JAK3
- LCK
Mechanisms of action (all sources)
- BTK INHIBITOR
- Tyrosine-protein kinase BTK inhibitor
- Bruton's tyrosine kinase (BTK) inhibitor
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Hematologic Agents
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Brutons Tyrosine Kinase Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- BGB-3111
- brukinsa
- Brukinsa
- RNOAOAWBMHREKO-UHFFFAOYSA-N
- ( inverted exclamation markA)-Zanubrutinib
- CHEMBL3973435
- SCHEMBL19742851
- SCHEMBL16208602
- BGB3111
- BDBM249900
- BCP29110
- BCP25045
- BCP25838
- AKOS032946689
- SB18877
- CS-6366
- ( inverted exclamation markA)-BGB-3111
- HY-101474
- US9447106, 27
- AG9MHG098Z
- zanubrutinibum
- BTK-InhB
- RefChem:57294
- DTXCID701510461
- Zanubrutinib (BGB-3111)
- Zanubrutinib [INN]
- Zanubrutinib [USAN]
- C27H29N5O3
- Brukinsa (TN)
- MFCD31567461
- Zanubrutinib (Standard)
- ZANUBRUTINIB [MI]
- Zanubrutinib [USAN:INN]
- UNII-AG9MHG098Z
- BGB-3111(Zanubrutinib)?
- ZANUBRUTINIB [WHO-DD]
- GTPL9861
- orb1299685
Reported adverse events
- Back pain
- Constipation
- Cough
- Dermatitis
- Dizziness
- Fatigue
- Hypertension
- Infection
- Musculoskeletal pain
- Pneumonia
- Pruritus
- Rash
Look up ZANUBRUTINIB in the interactive SynDRA portal →